A Rationale for Disease Modification A Brief Overview of UC-MSCs and DFPP Treatment. It is proposed that double-filtration plasmapheresis reduces the levels of circulating factors implicated in driving pathology and that UC-MSCs provide complement to downstream anti-inflammatory/regenerative signaling.
UC-MSCs were most effective for the treatment of DFPP
DFPP and stem cell therapy, UC-MSCs after DFPP, regenerative treatment with DFPP, sequential UC-MSCs and DFPP approach
The Rationale for UC-MSCs and DFPP Treatment
The rationale of using UC-MSCs and DFPP treatment lies in that, many chronic diseases are mediated not just by local tissue injury but also by an adverse systemic milieu. Double-filtration plasmapheresis (DFPP), in this context, is considered a blood purification strategy that helps eliminate some bulkier plasma components, and umbilical cord-derived mesenchymal stromal cells (UC-MSCs) are recognized as biologically active cells modulating inflammation and immune signals via paracrine activities.
For this reason, the combination is typically called a sequential strategy. We first give consideration to DFPP as a system treatment strategy to enhance the circulatory milieu, with UC-MSCs subsequently being viewed as an potential second-line biologic therapy that could complement and facilitate tissue-level repair. It is a plausible but still two weeks later in my mind far more hypothesis than established clinical fact.
What DFPP May Contribute First
Thus, DFPP draws attention as it may provide with the capability of removing certain circulating factors that help to sustain chronic low-grade inflammatory or metabolic stress. DFPP or direct flow plasma filtration is frequently characterized in this context as the reduction of markers such as low-density lipoprotein (LDL) cholesterol, other atherogenic lipoproteins and specific inflammatory plasma elements.
This is relevant, as a chronic unfavorable blood milieu might continue to demand stress from tissues even when no regenerative strategy is being implemented. DFPP might be additionally considered a shunting of part of the circulating burden initially from this perspective. DFPP is better considered not as a repair therapy per se, but rather as a conditioning or preparatory approach that could create an improved biologic microenvironment.
That distinction matters. DFPP should not be touted as a panacea. A closer interpretation might be that it could aid in reducing specific deleterious plasma factors prior to a regenerative plan being implemented at the second stage.
What UC-MSCs Add After DFPP
While DFPP is likely best considered as a means to optimize the circulating environment, UC-MSCs may represent the next-generation biologic tool designed to directly impact what occurs within the tissue microenvironment. The line between mesenchymal stromal cell as a direct replacement cell and a medicinal signaling cell is becoming more blurred.
Perhaps they will modulate inflammatory immune activity, direct macrophages from a pro-inflammatory to a non-antigen presenting state, shape T-cell balance toward either immunity/anti-immunity responses, establish a local cell-survival advantage via paracrine factors and intercellular vesicle signaling to further promote matrix remodeling. In this model, UC-MSCs are not primarily intended to give rise to fresh tissue themselves. Instead, they are examined in terms of how they can assist to create a more conducive healing space.
It is one of the fundamental reasons this type of UC-MSCs and DFPP treatment has been popular. While DFPP may alleviate a portion of the systemic inflammatory or metabolic burden initially, UC-MSCs should present downstream immunoregulatory and ectodermal tissue-supportive cues. This sequence in theory generates a more favorable biologic milieu than either treatment alone.
The Sequential Model’s Scientific Appeal
The allure of the combined model is that the two modalities seem to act at different tiers of disease biology.
DFPP: Mainly acts at the circulating plasma level
A discussion of UC-MSCs occurs primarily at the level of cell-signaling and tissue response.
So we can template the sequence like this:
Reduce harmful circulating factors first
Then we launch a therapy whose goal is to modulate tissue signaling and repair pathways
That is a concept that seems reasonable and internally consistent from the point of view of biology. This provides some rationale for studying the combination in settings where all these processes inflammation, fibrosis or metabolic burden may be operating. That said, MD pathways are arguably still more of a hypothesis-generating model than therapeutic algorithms.
The Implications of Current Evidence In Practice
The key point is that the science was ahead of the clinical evidence. However, although the biological rationale for post-DFPP use of UC-MSCs is attractive, this does not necessarily imply that this combination has been validated by robust standardized clinical evidence.
One of the biggest issues in regenerative medicine that keeps coming up is inconsistencies across protocols. Cell sources may differ. Homing efficiency may vary, and your prep methods are likely inconsistent. Treatment timing, dose, route and patient selection can vary from one setting to the other as well. For this reason, even if preliminary results seem encouraging, it is still hard to reach any strong conclusions.
This holds especially true for the paired-modality approaches like UC-MSCs and DFPP treatment. It therefore makes some sense conceptually, but is still not fully defined in terms of the exact clinical role.
Potential Clinical Relevance
Clinically, the most painstaking interpretation would be that this combination modality should be considered in pathological conditions where both systemic plasma-borne factors as well as local tissue inflammation or degeneration are operative. Within this context, DFPP could be viewed as a means of relieving some of the complicating background burden whereas UC-MSCs would provide some additional support for the next stage in stimulating regulation at the cellular and tissue injury-repair signaling levels.
You may find the following areas of interest:
chronic inflammatory conditions
fibrotic disease settings
metabolic-inflammatory overlap states
disorders in which the potential for tissue repair is limited by an unremittingly adverse internal milieu
Nonetheless, potential relevance must not be mistaken for evidence of routine clinical effectiveness
Why Caution Is Still Necessary
UC-MSCs and the course of DFPP treatment may need to proceed with caution. Thus, the strategy may be characterized as well-founded, but obviously still investigational and biologically plausible. Despite it not being portrayed as routine standard care, a definitive cure for regeneration and widely proven protocol.
However, that balanced language matters, as regenerative medicine is a field where biologic theory typically outpaces reasonably long-term standardized clinical evidence. It is an academic duty to explain both the hope and the doubt.
Clinical Interpretation
The conclusion that cannot be more balanced is the UC-MSCs and DFPP treatment could provide a sequential model of scientific interest. DFPP may minimize specific unwanted circulating plasma mediators initially, followed by anti-inflammatory, immunomodulatory and tissue-sustaining signaling from UC-MSCs.
This makes the combination interesting mechanistically. Instead, it should be described as an investigational approach rather than established routine clinical care. More robust clinical studies are required to establish patient selection, timing and dosing of administration, sequencing of treatment, and long-term benefit.
Final Takeaway
The use of UC-MSCs and DFPP can also be viewed as a sequential regenerative paradigm where DFPP may serve to pre-condition the peripheral environment initially followed by contributory signaling at the downstream level from UC-MSCs to promote immune regulation and tissue healing. It is a scientifically coherent and clinically interesting concept, but the potential role of this approach remains an evolving investigational strategy rather than an established standard treatment pathway.